

# Janice M Reichert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7372228/publications.pdf>

Version: 2024-02-01

66  
papers

9,229  
citations

76196

40  
h-index

54797

84  
g-index

111  
all docs

111  
docs citations

111  
times ranked

10202  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies to watch in 2022. MAbs, 2022, 14, 2014296.	2.6	239
2	Antibodies to watch in 2021. MAbs, 2021, 13, 1860476.	2.6	237
3	Antibodies to watch in 2020. MAbs, 2020, 12, 1703531.	2.6	381
4	Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18, 585-608.	21.5	755
5	Antibodies to watch in 2019. MAbs, 2019, 11, 219-238.	2.6	387
6	Antibodies to watch in 2018. MAbs, 2018, 10, 183-203.	2.6	223
7	Antibodies to watch in 2017. MAbs, 2017, 9, 167-181.	2.6	225
8	Note of appreciation to reviewers. MAbs, 2017, 9, 1-4.	2.6	3
9	Note of appreciation to reviewers. MAbs, 2016, 8, 653-657.	2.6	0
10	Antibodies to watch in 2016. MAbs, 2016, 8, 197-204.	2.6	163
11	Antibody engineering & therapeutics, the annual meeting of the antibody society December 7â€“10, 2015, San Diego, CA, USA. MAbs, 2016, 8, 617-652.	2.6	7
12	Note of appreciation to reviewers. MAbs, 2015, 7, 281-285.	2.6	0
13	Antibodies to watch in 2015. MAbs, 2015, 7, 1-8.	2.6	149
14	Antibody-drug conjugates. MAbs, 2014, 6, 15-17.	2.6	131
15	Antibodies to watch in 2014. MAbs, 2014, 6, 5-14.	2.6	90
16	Antibodies to watch in 2014. MAbs, 2014, 6, 799-802.	2.6	41
17	Future directions for peptide therapeutics development. Drug Discovery Today, 2013, 18, 807-817.	3.2	633
18	Antibody Engineering and Therapeutics Conference. MAbs, 2013, 5, 817-825.	2.6	1

#	ARTICLE	IF	CITATIONS
19	Which are the antibodies to watch in 2013?. MAbs, 2013, 5, 1-4.	2.6	107
20	Antibodies to watch in 2013. MAbs, 2013, 5, 513-517.	2.6	71
21	Approval of the first biosimilar antibodies in Europe. MAbs, 2013, 5, 621-623.	2.6	114
22	7th Annual European Antibody Congress 2011. MAbs, 2012, 4, 134-152.	2.6	7
23	mAbs's communication networks. MAbs, 2012, 4, 133-133.	2.6	0
24	IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA. MAbs, 2012, 4, 153-181.	2.6	10
25	Which are the antibodies to watch in 2012?. MAbs, 2012, 4, 1-3.	2.6	65
26	Marketed therapeutic antibodies compendium. MAbs, 2012, 4, 413-415.	2.6	320
27	Marketing approval of mogamulizumab. MAbs, 2012, 4, 419-425.	2.6	193
28	The future of antibodies as cancer drugs. Drug Discovery Today, 2012, 17, 954-963.	3.2	115
29	Antibody-based therapeutics to watch in 2011. MAbs, 2011, 3, 76-99.	2.6	207
30	Bispecific antibodies and ADCs. MAbs, 2011, 3, 329-330.	2.6	15
31	Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs, 2011, 3, 415-416.	2.6	156
32	The amazing, multipurpose antibody. MAbs, 2011, 3, 221-222.	2.6	10
33	Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 2010, 9, 767-774.	21.5	873
34	Editorial for PEDS special issue on antibodies. Protein Engineering, Design and Selection, 2010, 23, 153-154.	1.0	2
35	Metrics for antibody therapeutics development. MAbs, 2010, 2, 695-700.	2.6	70
36	Antibodies to watch in 2010. MAbs, 2010, 2, 84-100.	2.6	86

#	ARTICLE	IF	CITATIONS
37	mAb therapeutic products and risk management. MAb, 2010, 2, 1-2.	2.6	9
38	Letter from the Editor. MAb, 2010, 2, 107-107.	2.6	3
39	Progress atmAbs. MAb, 2010, 2, 593-593.	2.6	1
40	Probabilities of success for antibody therapeutics. MAb, 2009, 1, 387-389.	2.6	13
41	Letter from the Editor. MAb, 2009, 1, 91-92.	2.6	0
42	Global antibody development trends. MAb, 2009, 1, 86-87.	2.6	22
43	Letter from the Editor. MAb, 2009, 1, 189-189.	2.6	0
44	Development trends for therapeutic antibody fragments. Nature Biotechnology, 2009, 27, 331-337.	9.4	262
45	A decade of the Fast Track programme. Nature Reviews Drug Discovery, 2008, 7, 885-886.	21.5	5
46	Development trends for new cancer therapeutics and vaccines. Drug Discovery Today, 2008, 13, 30-37.	3.2	120
47	Monoclonal Antibodies as Innovative Therapeutics. Current Pharmaceutical Biotechnology, 2008, 9, 423-430.	0.9	235
48	Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections. BioDrugs, 2007, 21, 1-7.	2.2	21
49	Development trends for monoclonal antibody cancer therapeutics. Nature Reviews Drug Discovery, 2007, 6, 349-356.	21.5	359
50	Anti-infective monoclonal antibodies: perils and promise of development. Nature Reviews Drug Discovery, 2006, 5, 191-195.	21.5	54
51	Trends in US approvals: new biopharmaceuticals and vaccines. Trends in Biotechnology, 2006, 24, 293-298.	4.9	32
52	Monoclonal antibody successes in the clinic. Nature Biotechnology, 2005, 23, 1073-1078.	9.4	682
53	Recombinant protein therapeuticsâ€™ success rates, market trends and values to 2010. Nature Biotechnology, 2004, 22, 1513-1519.	9.4	286
54	Monoclonal antibodies market. Nature Reviews Drug Discovery, 2004, 3, 383-384.	21.5	98

#	ARTICLE	IF	CITATIONS
55	Trends in development and approval times for new therapeutics in the United States. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 695-702.	21.5	214
56	Clinical development of therapeutic recombinant proteins. <i>BioTechniques</i> , 2003, 35, 176-185.	0.8	11
57	Public and Private Sector Contributions to the Discovery and Development of High-Impact Drugs. <i>American Journal of Therapeutics</i> , 2002, 9, 543-555.	0.5	28
58	Therapeutic cancer vaccines on trial. <i>Nature Biotechnology</i> , 2002, 20, 659-663.	9.4	10
59	Therapeutic monoclonal antibodies: trends in development and approval in the US. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 110-8.	2.8	25
60	Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 51, 1-7.	2.0	10
61	Monoclonal antibodies in the clinic. <i>Nature Biotechnology</i> , 2001, 19, 819-822.	9.4	162
62	The Effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the Development and Approval of Therapeutic Medicines. <i>Drug Information Journal</i> , 2001, 35, 85-94.	0.5	7
63	Clinical Development of Therapeutic Medicines: A Biopharmaceutical Versus Pharmaceutical Product Comparison. <i>Drug Information Journal</i> , 2001, 35, 337-346.	0.5	9
64	New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. <i>Trends in Biotechnology</i> , 2000, 18, 364-369.	4.9	57
65	Total Syntheses of (+)-Acetiphycin and (+)-trans-20,21-Didehydroacetiphycin. <i>Journal of the American Chemical Society</i> , 1997, 119, 10935-10946.	6.6	48
66	Total Syntheses of (+)-Acetiphycin and (+)-trans-20,21-Didehydroacetiphycin. <i>Journal of the American Chemical Society</i> , 1995, 117, 12013-12014.	6.6	60